Podium to Practice: ASH® 2025 – MULTIPLE MYELOMA: Long-Term PFS Benefit of Cilta-Cel in Standard-Risk R/R MM
OR
[magic_login_form]
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Studies / Trials Discussed
ID 94 – Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma
Studies/trials discussed:
ID 94 – Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.